Motus GI Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Motus GI reported a significant 40% revenue increase for Q3 2021 compared to Q2 2021, marking its fifth consecutive quarter of revenue growth. Revenue reached $141,000, up from $33,000 year-over-year. The company is preparing to file a 510(k) submission for its Pure-Vu EVS system by the end of 2021, which enhances operational efficiency. Additionally, Motus GI plans a multi-center trial targeting reimbursement for high-need outpatient procedures involving over 20 million colonoscopies annually in the U.S. As of September 30, 2021, the company reported a net loss of $4.8 million.
- 40% revenue increase compared to Q2 2021.
- Fifth consecutive quarter of revenue growth.
- Successfully secured a $12 million credit facility.
- Reported a net loss of $4.8 million in Q3 2021.
- Cash used in operating activities increased to $3.1 million.
- Reported approximately
40% increase in revenue compared to Q2 2021 - On track to file a 510(k) submission to FDA by end of 2021 for Pure-Vu EVS, an advanced, next-generation system that will enhance procedural ease of use and speed of deployment
- Designing a multi-center, randomized controlled trial to support reimbursement of Pure-Vu for high need outpatients, a subset of the US market of more than 20 million total annual colonoscopies
FORT LAUDERDALE, Fla., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, today reported its financial results for the third quarter and nine months ended September 30, 2021, and provided a corporate update.
“I am pleased with our team’s ability to drive increased utilization of Pure-Vu® in our initial set of U.S. hospital accounts as well as convert more targeted accounts to active customers. This helped us deliver revenue growth of approximately
“We are in the process of preparing a 510(k) application for the Pure-Vu EVS, our third generation of the Pure-Vu System, which we expect to submit to the U.S. FDA by the end of this year. The Pure-Vu EVS represents a significant advancement of our technology, including rapid set-up in less than 90 seconds, the ability to load our sleeve on a ‘dirty’ scope in the procedure room, and improved overall navigation, handling and ease of use. We believe Pure-Vu EVS can accelerate physician interest and adoption of our technology and as such we plan to thoughtfully expand our commercial footprint over the next couple of quarters in anticipation of increased demand, allowing us to have local representation in the major U.S. GI markets,” added Mr. Moran.
“Additionally, we continue to report positive new clinical data for the Pure-Vu System. We recently announced the presentation of positive data from an independent single-center study of the Pure-Vu System as an adjunct to colon cleansing in 40 patients with inadequate bowel preparation at the 2021 American College of Gastroenterology (ACG) Annual Scientific Meeting. We are also preparing for the initiation of a large multi-center, randomized control trial to support Pure-Vu reimbursement for the large outpatient colorectal cancer screening and diagnosis market,” concluded Mr. Moran.
Third Quarter and Recent Business Highlights
- Procedure Growth – The Company increased sales of disposable sleeves for procedures using the Pure-Vu System, which resulted in the fifth sequential quarter of revenue growth.
- New Customer Agreements:
- Through the end of the third quarter of 2021, approximately ten key U.S. hospitals have either purchased capital equipment and disposable sleeves or signed a 12 month committed-volume agreement.
- Completed the capital sale of a Pure-Vu System to Memorial Herman Hospital in Houston in the third quarter of 2021, opening the door to the Memorial Herman Health System, which consists of 17 affiliated hospitals and making this placement an important initial customer hospital in a large health system.
- 510(k) Submission for Pure-Vu EVS to the FDA - The Company expects to submit a 510(k) application for the Pure-Vu EVS System to the FDA by the end of 2021. In addition, the Company is currently preparing for the commercial launch of the Pure-Vu EVS, pending U.S. FDA clearance. This is the third generation of the Pure-Vu System, which has been under development for the last 18 months.
- Outpatient Reimbursement Strategy:
- The Company is advancing its strategy to secure reimbursement for the Pure-Vu System when used for certain outpatient colonoscopies, including a multi-center, randomized controlled trial.
- Clinical Data Generation:
- Announced positive new data from an independent study at the University of Texas Medical Branch, Galveston that supports use of the Pure-Vu System for screening and emergency colonoscopies for patients with inadequate bowel preparation.
- Announced the expansion of the EU Clinical study exploring limited bowel prep for CRC screeening with enrollment of initial patients at a second clinical site, the GastroZentrum Lippe, one of the top private endoscopy clinics in Germany.
- Continuing the investigator-initiated clinical study being conducted by a leading U.S. academic medical center to examine using the Pure-Vu System in patients with lower GI bleeding with minimal pre-procedural bowel prep.
- Exploration of Upper GI Bleed Market - Commenced initial pilot cases of the Pure-Vu Upper GI product, which is focused on targeted evaluations by existing Pure-Vu accounts already using the system for colonoscopy. The purpose of these initial series of procedures is to demonstrate clinical utility of the Upper GI product and gain real-world learning to support improvements to a future Pure-Vu EVS-based Upper GI system.
- Enhanced Financial Flexibility – Secured an expanded
$12.0 million credit facility to support the Company’s commercial sales growth and advancement of its additional value creation drivers, which also replaces the previous$8 million term loan agreement with Silicon Valley Bank and removes the$10.0 million minimum cash balance liquidity covenant.
Financial Results for the Quarter Ended September 30, 2021
The Company reported revenue of approximately
For the three months ended September 30, 2021, the Company reported a net loss of
During the third quarter, net cash used in operating activities and for the purchase of fixed assets was
The Company reported
Conference Call:
The Motus GI management team has scheduled a conference call for today, November 12th, at 8:30 a.m. ET to discuss these results. To access the conference call, investors are invited to dial (877) 407-0792 (U.S. and Canada) or (201) 689-8263 (International). The conference ID number is 13723885. A live audio webcast can be accessed by visiting the investor relations section of the Company’s website, www.motusgi.com or http://public.viavid.com/index.php?id=146872. A replay of the webcast will be archived on the Motus GI website for 90 days following the event.
About Motus GI
Motus GI Holdings, Inc. is a medical technology company, with subsidiaries in the U.S. and Israel, providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions.
For more information, visit www.motusgi.com and connect with the Company on Twitter, LinkedIn and Facebook.
Forward-Looking Statements
This press release contains certain forward-looking statements. Forward-looking statements are based on the Company's current expectations and assumptions. The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements. These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms, including without limitation, risks related to the Company’s cost reduction plan, the cost savings and the cash expenses related to the implementation of the plan, risks related to the continued impact of the COVID-19 pandemic, risks inherent in the development and commercialization of potential products, possible or assumed future results of operations, business strategies, potential grow opportunities, uncertainty in the timing and results of clinical trials or regulatory approvals, maintenance of intellectual property rights or other risks discussed in the Company’s Form 10-K filed on March 16, 2021, and its other filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Investor Contact:
Bob Yedid
LifeSci Advisors
(646) 597-6989
bob@lifesciadvisors.com
Motus GI Holdings, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
(in thousands, except share and per share amounts)
| September 30, | December 31, | |||||||
| 2021 | 2020 | |||||||
| (unaudited) | ||||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 23,652 | $ | 20,819 | ||||
| Accounts receivable | 181 | 35 | ||||||
| Inventory | 515 | 805 | ||||||
| Prepaid expenses and other current assets | 530 | 448 | ||||||
| Total current assets | 24,878 | 22,107 | ||||||
| Fixed assets, net | 1,438 | 1,178 | ||||||
| Right-of-use assets | 749 | 766 | ||||||
| Other non-current assets | 13 | 13 | ||||||
| Total assets | $ | 27,078 | $ | 24,064 | ||||
| Liabilities and Shareholders’ Equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable and accrued expenses | $ | 2,337 | $ | 2,333 | ||||
| Operating lease liabilities - current | 300 | 238 | ||||||
| Other current liabilities | 9 | 60 | ||||||
| Term debt, net of debt discount of | - | 7,979 | ||||||
| Total current liabilities | 2,646 | 10,610 | ||||||
| Contingent royalty obligation | 1,769 | 1,617 | ||||||
| Operating lease liabilities - non-current | 457 | 547 | ||||||
| Convertible note, net of unamortized debt discount of | 3,818 | - | ||||||
| Long-term debt, net of unamortized debt discount of | 4,608 | - | ||||||
| Total liabilities | 13,298 | 12,774 | ||||||
| Commitments and contingent liabilities (Note 9) | ||||||||
| Shareholders’ equity | ||||||||
| Preferred stock | - | - | ||||||
| Common stock | 5 | 3 | ||||||
| Additional paid-in capital | 131,711 | 115,008 | ||||||
| Accumulated deficit | (117,936 | ) | (103,721 | ) | ||||
| Total shareholders’ equity | 13,780 | 11,290 | ||||||
| Total liabilities and shareholders’ equity | $ | 27,078 | $ | 24,064 | ||||
Motus GI Holdings, Inc. and Subsidiaries
Condensed Consolidated Statements of Comprehensive Loss
(unaudited, in thousands, except share and per share amounts)
| Three Months Ended September 30, | Nine months Ended September 30, | |||||||||||||||
| 2021 | 2020 | 2021 | 2020 | |||||||||||||
| Revenue | $ | 141 | $ | 33 | $ | 292 | $ | 62 | ||||||||
| Operating expenses: | ||||||||||||||||
| Cost of revenue - sales | 65 | 32 | 135 | 72 | ||||||||||||
| Cost of revenue - impairment of inventory | 186 | - | 186 | - | ||||||||||||
| Research and development | 1,187 | 1,160 | 4,040 | 4,359 | ||||||||||||
| Sales and marketing | 725 | 509 | 2,196 | 2,954 | ||||||||||||
| General and administrative | 2,315 | 2,155 | 7,104 | 7,432 | ||||||||||||
| Total costs and expenses | 4,478 | 3,856 | 13,661 | 14,817 | ||||||||||||
| Operating loss | (4,337 | ) | (3,823 | ) | (13,369 | ) | (14,755 | ) | ||||||||
| Gain (loss) on change in estimated fair value of contingent royalty obligation | (35 | ) | (3 | ) | (152 | ) | 248 | |||||||||
| Loss on extinguishment of debt | (237 | ) | - | (237 | ) | - | ||||||||||
| Finance expense, net | (216 | ) | (117 | ) | (450 | ) | (348 | ) | ||||||||
| Other income | 5 | - | 5 | - | ||||||||||||
| Foreign currency loss | (4 | ) | (1 | ) | (12 | ) | (4 | ) | ||||||||
| Net loss | (4,824 | ) | (3,938 | ) | (14,215 | ) | (14,859 | ) | ||||||||
| Deemed dividends from warrant issuance | - | - | (6,145 | ) | - | |||||||||||
| Net loss attributable to common shareholders | $ | (4,824 | ) | $ | (3,938 | ) | $ | (20,360 | ) | $ | (14,859 | ) | ||||
| Basic and diluted loss per common share: | ||||||||||||||||
| Net loss | $ | (0.10 | ) | $ | (0.13 | ) | $ | (0.31 | ) | $ | (0.51 | ) | ||||
| Net loss attributable to common shareholders | $ | (0.10 | ) | $ | (0.13 | ) | $ | (0.44 | ) | $ | (0.51 | ) | ||||
| Weighted average number of common shares outstanding, basic and diluted | 48,241,188 | 30,422,265 | 46,419,643 | 29,366,154 | ||||||||||||
FAQ
What were Motus GI's Q3 2021 financial results?
What is the outlook for Motus GI's Pure-Vu EVS system?
How much loss did Motus GI incur in Q3 2021?
What are the key developments for Motus GI's outpatient strategy?
